Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing

The regulatory bodies request full sequence data assessment both for innovator and biosimilar monoclonal antibodies (mAbs). Full sequence coverage is typically used to verify the integrity of the analytical data obtained following the combination of multiple LC-MS/MS datasets from orthogonal proteas...

Descripción completa

Detalles Bibliográficos
Autores principales: Resemann, Anja, Jabs, Wolfgang, Wiechmann, Anja, Wagner, Elsa, Colas, Olivier, Evers, Waltraud, Belau, Eckhard, Vorwerg, Lars, Evans, Catherine, Beck, Alain, Suckau, Detlev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966597/
https://www.ncbi.nlm.nih.gov/pubmed/26760197
http://dx.doi.org/10.1080/19420862.2015.1128607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966597/
https://www.ncbi.nlm.nih.gov/pubmed/26760197
http://dx.doi.org/10.1080/19420862.2015.1128607

Ejemplares similares